Pierangela Sepe

ORCID

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 4

Top Venues

Therapeutic advances in medical oncology

Tumori

This page only lists publications with an associated author ORCID identifier.

Publications

Pierangela Sepe, Giuseppe Procopio, Chiara Carlotta Pircher, Umberto Basso, Orazio Caffo, Vera Cappelletti, Melanie Claps, Ugo De Giorgi, Lucia Fratino, Valentina Guadalupi, Patrizia Miodini, Cinzia De Marco, Bruno Perrucci, Alessia Mennitto, Daniele Santini, Francesco Spina, Marco Stellato, Filippo de Braud, Elena Verzoni
A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study). Therapeutic advances in medical oncology 16 (2024)
Pierangela Sepe, Giuseppe Procopio, Chiara Carlotta Pircher, Umberto Basso, Orazio Caffo, Vera Cappelletti, Melanie Claps, Ugo De Giorgi, Lucia Fratino, Valentina Guadalupi, Patrizia Miodini, Cinzia De Marco, Bruno Perrucci, Alessia Mennitto, Daniele Santini, Francesco Spina, Marco Stellato, Filippo de Braud, Elena Verzoni
A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study). Therapeutic advances in medical oncology 16 (2024)
Sebastiano Buti, Francesca Trentini, Pierangela Sepe, Melanie Claps, Luca Isella, Elena Verzoni, Giuseppe Procopio
BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients. Tumori (2022)
Giuseppe Procopio, Mélanie Claps, Chiara Pircher, Luca Porcu, Pierangela Sepe, Valentina Guadalupi, Ugo De Giorgi, Davide Bimbatti, Franco Nolè, Francesco Carrozza, Sebastiano Buti, Roberto Iacovelli, Chiara Ciccarese, Cristina Masini, Cinzia Baldessari, Laura Doni, Antonio Cusmai, Angela Gernone, Sarah Scagliarini, Sandro Pignata, Filippo de Braud, Elena Verzoni
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03). Tumori (2022)

Pierangela Sepe.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Pierangela Sepe